Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: GlobeNewswire
Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin avß8 and avß1 inhibitor, in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI) -refractory advanced or metastatic solid tumors. Interim results demonstrated PLN-101095 anti-tumor activity in combination with pembrolizumab, with three partial responses observed in cohort three at the 1000 mg administered orally twice daily (BID) dose, representing a 50% objective response rate (ORR) at the highest dose tested to date. PLN-101095 was generally well tolerated across all doses tested. Nine patients with
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
News
- Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid TumorsGlobeNewswire
- Pliant Therapeutics to Participate in the Piper Sandler Healthcare ConferenceGlobeNewswire
- Pliant Therapeutics (NASDAQ:PLRX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PLRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- Pliant Therapeutics (NASDAQ:PLRX) had its price target lowered by analysts at Royal Bank Of Canada from $3.00 to $2.00. They now have a "sector perform" rating on the stock.MarketBeat
- Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswire
PLRX
Earnings
- 11/6/25 - Beat
PLRX
Sec Filings
- 12/16/25 - Form 8-K
- 12/8/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- PLRX's page on the SEC website